Barclays analyst Peter Lawson assigned a Buy rating to Tango Therapeutics (TNGX – Research Report) on June 23 and set a price target of $18.00. The company’s shares closed last Friday at $3.74.
According to TipRanks, Lawson is a 3-star analyst with an average return of 2.0% and a 42.25% success rate. Lawson covers the Healthcare sector, focusing on stocks such as ImmunoGen, Relay Therapeutics, and Iovance Biotherapeutics.
Tango Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $15.75.
See Insiders’ Hot Stocks on TipRanks >>
Based on Tango Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.77 million and a GAAP net loss of $28.01 million. In comparison, last year the company earned a revenue of $5.76 million and had a GAAP net loss of $27.85 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BCTG Acquisition Corp is a blank check company.
Read More on TNGX:
